BOSTON, Mass. ( TheStreet) -- The year is coming to an end but the biotech calendar is still buzzing with important, stock-moving events right up to New Year's Eve. Before I get to the calendar, I want to mention some key December biotech catalysts without a fixed date but which investors should still be keeping in mind. Delcath Systems ( DCTH) is supposed to complete the U.S. approval application for its liver tumor Chemosaturation System before the end of the month. RXi Pharmaceuticals ( RXII) has promised investors a significant drug development partnership before year's end. Investors will also be eager to hear the outcome of the December meeting between Arena Pharmaceuticals ( ARNA) and FDA following the latter's rejection of Arena's obesity drug lorcaserin. Cell Therapeutics ( CTIC) is expecting a ruling on its appeal of the FDA's rejection of the company's lymphoma drug pixantrone. Amgen ( AMGN) will announce results from a phase III trial investigating whether treatment with Xgeva can prevent the spread of prostate cancer to the bone. Incyte Pharmaceuticals ( INCY) is expected to announce top-line results from a U.S. phase III study of INCB18424 in myelofibrosis. Celgene ( CELG) could have data from two important, phase III clinical trials before the books close on 2010: A phase III study of Abraxane in front-line non-small cell lung cancer and a phase III study of Amrubicin in small-cell lung cancer (although this latter study may not be completed until early 2011.) Corcept Therapeutics ( CORT) will announce top-line results from a phase III study of Corlux in Cushing's Syndrome during December. Now, to the December biotech calendar: Dec. 2: Affymax ( AFFY) provides an update on regulatory plans for the experimental anemia dru Hematide. Exelixis ( EXEL) investor/analyst meeting. Targacept ( TRGT) investor/analyst meeting. Dec. 3: Orexigen Therapeutics ( OREX): FDA should release review documents on the obesity drug Contrave in advance of the advisory panel meeting. Dec. 4-7: American Society of Hematology annual meeting: Important data presentations from Onyx Pharmaceuticals ( ONXX), Seattle Genetics ( SGEN), Celgene, and others. Dec. 5-9: American College of Neuropsychopharmacology (ACNP) annual meeting. Dec. 7: Orexigen Therapeutics: FDA advisory panel reviewing the obesity drug Contrave.
I'll be live-blogging the Contrave panel, sign up below for an email reminder. Dec. 8-12: San Antonio Breast Cancer Symposium
Dec. 9: FDA approval decision for Human Genome Sciences' ( HGSI) lupus drug Benlysta. Dec. 14: Onyx Pharmaceuticals investor/analyst meeting. Dec. 16: FDA approval decision for AstraZeneca's ( AZN) blood thinner Brilinta. Dec. 29: FDA approval decision for Alimera Sciences' ( ALIM) Iluvien for treatment of diabetic macular edema. FDA approval decision for MannKind's ( MNKD) inhaled insuline device Afrezza --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.